Anti-Chlamydial Antibiotic Therapy for Symptom Improvement in Peripheral Artery Disease | Zendy

Michael R. Jaff | Zendy; Rita Dale | Zendy; Mark A. Creager | Zendy; Raymond J. Lipicky | Zendy; John Constant | Zendy; Lee Ann Campbell | Zendy; William R. Hiatt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-Chlamydial Antibiotic Therapy for Symptom Improvement in Peripheral Artery Disease

Author(s) -

Michael R. Jaff,

Rita Dale,

Mark A. Creager,

Raymond J. Lipicky,

John Constant,

Lee Ann Campbell,

William R. Hiatt

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.815308

Subject(s) - medicine , intermittent claudication , claudication , clinical endpoint , placebo , confidence interval , arterial disease , randomized controlled trial , surgery , cardiology , physical therapy , vascular disease , pathology , alternative medicine

A potentially strong association exists between Chlamydia pneumoniae and atherosclerosis, but the clinical benefits of antibiotic therapy have not been demonstrated. Preliminary studies of antibiotic therapy in peripheral artery disease have shown a decreased need for revascularization and improved walking ability. The objective of this phase-III trial was to assess the effect of a potent anti-Chlamydial agent, rifalazil, on peak walking time in patients with symptomatic peripheral artery disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research